Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305676 · ClinicalTrials.gov registry record
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
A clinical trial of Oropharyngeal Cancer and HPV-Related Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT06305676: Recruiting study of Oropharyngeal Cancer and HPV-Related Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06305676 is a study of Oropharyngeal Cancer and HPV-Related Carcinoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 400 participants, above the 174-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (130% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305676, a study of Oropharyngeal Cancer and HPV-Related Carcinoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh).
Primary Outcome
A 95% one-sided confidence interval using the Wilson method will be obtained for sensitivity for the early Oropharyngeal Cancer cases and late Oropharyngeal Cancer cases.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST combined HPV 16 DNA and host gene methylation oral biomarker panel
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2029-01 |
What NCT06305676 shows while recruiting
NCT06305676 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 174-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (130% higher).
The record links to 2 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which combined HPV 16 DNA and host gene methylation oral biomarker panel is the first listed.
NCT06305676 reports a single indexed study location in Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06305676 about?
NCT06305676 is a clinical study titled "Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)". Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, a...
What is the current status of trial NCT06305676?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-01-22. Estimated completion is 2029-01.
What conditions does trial NCT06305676 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer, HPV-Related Carcinoma.
What interventions are being tested in trial NCT06305676?
The interventions under investigation include: combined HPV 16 DNA and host gene methylation oral biomarker panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06305676?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305676 being conducted?
This trial has 2 study locations across Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06305676's enrollment target sits among peer trials
400 4th of 25 higher than 22 of 25 other Oropharyngeal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Liposomal Bupivacaine and Transoral Robotic Surgery
RECRUITING
-
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
RECRUITING · Phase 3
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI